Substituted indole derivatives

Details Substituted indole derivatives Substituted indole derivatives

Filed on

2004-10-01

Date issued

2008-11-04

Examiner

McKane, Joseph (Department: 1626)

Patent Class

Drug, bio-affecting and body treating compositions

SubClass

Designated organic active ingredient containing

SubSubClass

Having -c-, wherein x is chalcogen, bonded directly to...

Other Related Categories

C514S338000, C548S432000, C546S276700

Type

Reexamination Certificate

Status

active

Patent number

07446122

Description

ABSTRACT:
Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

REFERENCES:
patent: 3590028 (1971-06-01), Arcamone et al.
patent: 3843681 (1974-10-01), Demerson et al.
patent: 3939178 (1976-02-01), Demerson et al.
patent: 4012448 (1977-03-01), Smith et al.
patent: 4041169 (1977-08-01), Demerson et al.
patent: 4070371 (1978-01-01), Demerson et al.
patent: 4179503 (1979-12-01), Asselin et al.
patent: 4686213 (1987-08-01), Ferdinandi et al.
patent: 4748252 (1988-05-01), Ferdinandi et al.
patent: 5420289 (1995-05-01), Musser et al.
patent: 5561151 (1996-10-01), Young et al.
patent: 5776967 (1998-07-01), Kreft et al.
patent: 5824699 (1998-10-01), Kreft et al.
patent: 5830911 (1998-11-01), Failli et al.
patent: 5955504 (1999-09-01), Wechter et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 6025353 (2000-02-01), Masferrer et al.
patent: 6255347 (2001-07-01), Xiaotao et al.
patent: 6545034 (2003-04-01), Carson et al.
patent: 6552055 (2003-04-01), Spiegelman et al.
patent: 6573292 (2003-06-01), Nardella
patent: 7314886 (2008-01-01), Chao et al.
patent: 2002/0015943 (2002-02-01), Bienz
patent: 2002/0107280 (2002-08-01), McLaren et al.
patent: 2003/0064384 (2003-04-01), Hung et al.
patent: 1299577 (1992-04-01), None
patent: 1 436 893 (1976-05-01), None
patent: WO 02/12188 (2002-02-01), None
patent: WO 02/088081 (2002-11-01), None
patent: WO 02/092635 (2002-11-01), None
patent: WO 2005026112 (2005-03-01), None
Brenna et al., “New Enzymatic and Chemical Approaches to Enantiopure Etodolac”,Tetrahedron(1997), vol. 53, No. 52, pp. 17769-17780.
Demerson et al., “Chemistry and Antiinflammatory Activities of Prodolic-Acid and Related 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-alkanoic Acids”,Journal of Medicinal Chemistry(1975), vol. 18, No. 2, pp. 189-191.
Amir et al., 2003, J. Biol. Chem., 278:30828-30834.
Araki et al., “Regulation of Cyclooxygenase-2 Expression by the Wnt and Ras Pathways”, Cancer Research (2003), vol. 63, pp. 728-734.
Baek et al., 2001 Mol. Pharmacol. 59:901-908.
Blaker et al., 1999 Genes Chromosomes Cancer 25:399-402.
Briata et al., Mol. Cell., 12:1201-1211, 2003.
Carayol et al., 2002, Am. J. Respir Cell Mol Biol., 26:341-347.
Chan et al., 1999, J. Pharmacol Exp. Ther. 290:551-560.
Chung et al., “Regulation of leukemic cell adhesion, proliferation, and survival by β-catenin” 2002 Blood 100:982-990.
Dihlmann et al., “Reduction of β-catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin is Caused by an Increased Stabilization of Phosphorylated β-catenin”, Molecular Cancer Therapeutics, (2003), vol. 2, pp. 509-516.
Dihlmann et al., Oncogene 20:645-653, 2001.
Eriksen et al., “NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo”, 2002 J. Clinical Invest. 112:440-449.
Fukuchi et al., 1998 Cancer Res. 58:3526-3528.
Garcia-Rostan et al., 1999 Cancer Res. 59:1811-1815.
He et al., “PPARδ is an APC-Regulated target of Nonsteroidal Anti-Inflammatory Drugs”, 1999 Cell 99:335-345.
Hinz et al., 2002 J. Pharm. Exp. Ther. 300:367-375.
Iwao et al., Jpn. J. cancer Res., 90:205-209, 1999.
Korinek et al., “Constitutive Transciptional Activation by a β-catenin-Tcf Complex in APC-/-Colon Carcinoma” 1997, Science, 275:1784-1787.
Lehmann et al., 1997, J. Biol. Chem., 272:3406-3410.
Li et al., “β-Catenin Signaling”, Cancer Biology and therapy (2002), vol. 1, No. 6, 621-625.
Lim et al., “Significance of E-cadherin/β-catenin complex and cyclin D1 in breast cancer”, Oncology Reports (2002), vol. 9, 915-928.
Lin et al., 2000 Proc. Natl. Acad. Sci., 97:4262-4266.
Mardini et al., “Selective inhibitors of Cyclooxygenase-2: A growing class of anti-inflammatory drugs”, Molecular Inventions (2001), vol. 1, No. 1, 30-38.
McEntee et al., 1999 Carcinogenesis 20:635-640.
Miyoshi et al., “β-catenin: a transforming actor on many stages”, Breast Cancer Research (2003) vol. 5, No. 2, 63-68.
Muthukkauppah et al., 1982, J. Natl. Cancer Inst., 69:699-708.
Noda et al., 2002 J. Gastrointerol. 37(11):896-904.
Ohta et al., 2002 Int. J. Oncol. 21:37-42.
Okamura et al., 2003 Cancer Res. 63:728-734.
Park, Ben Ho et al., “Genetic disruption of PPARδ decreases the tumorigencity of human colon cancer cells”, Proc. Natl. Acad. Sci., (2001), vol. 98, No. 5., pp. 2598-2603.
Polakis, “Wnt signaling and cancer”, 2000 Genes and Development, 14:1837-1851.
Riendeau et al., 1997, Can. J. Physiol. Pharmacol., 75:1088-1095.
Romijn et al., 1988 Prostate 12:99-110.
Rubinfeld et al., 1997 Science 275:1790-1792.
Sakai et al., 2002, Int. J. Oncology 21:547-552.
Sauter et al., “Antisense Cyclin D1 Induces Apoptosis and Tumor Shrinkage in Human Squamous Carcinomas”, Cancer Research (1999), vol. 59, 4876-4881.
Shan et al., J.Pharm. Sci., 86 (7), 765-767, 1997.
Shiff et al., “The Role of Cyclooxygenase Inhibition in the Antineoplastic Effects of Nonsteroidal Antiinflammatory Drugs (NSAIDs)”, J. Exp. Med. (1999), vol. 190, No. 4, 445-450.
Shimada et al., 2002 Gut 50:658-664.
Swinney et al., 1997, J. Biol. Chem. 272:12393-12398.
Takayasu et al., 2001, Clin. Cancer Research, 7:901-908.
Tetsu et al., Nature 398:422-426, 1999.
Ueta et al., “β-catenin and cyclin D1 expression in human hepatocellular carcinoma” (2002) Oncology Reports 9:1197-1203.
Wakita et al., 2001, Cancer Res., 61:854-858.
Warner et al., 1999, Proc. Natl. Acad. Sci., 96:7563-7568.
Weggen et al., 2001 Nature 414:212-216.
Winter et al., (1962), Proc. Soc. Exp. Biol. Med. 111:544.
Wong et al., “β-catenin-a linchpin in Colorectal Carcinogensis?”, American Journal of Pathology (2002), vol. 160, No. 2, 389-401.
Xu et al., 1994 Int. J. Cancer 59:383-387.
Zhang et al., “Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (NSAIDs) on Cyclooxygenase-null Embryo Fibroblasts”, Journal of Experimental Medicine (1999), vol. 190, No. 4, 451-459.
Hedvat et al.,Cancer Cell(2004), vol. 5, pp. 565-574.
Lu et al.,Proc. Natl. Acad. Sci.(2004), vol. 101, No. 9, pp. 3118-3123.

Affiliated with

Also associated with

Rating

Substituted indole derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted indole derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted indole derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4040491